A Phase 2, Multicenter, Open-Label, Dose-Optimization Study Evaluating Telomere-Targeting Agent THIO Sequenced with Cemiplimab in Patients with Advanced NSCLC: Updated Results.Tomasz Jankowski,Tibor Csoszi,Laszlo Urban, Tunde Nagy, Nataliya Chilingirova, Maria Cholakova, Rohit Joshi, Melissa M. Moore,Rodryg Ramlau, Szabolcs Soter, Marek Kotlarski, Krassimir Dimitrov Koynov, Andrzej Mruk,Brenton Seidl, Velko Minchev, Veronika Muller,Vlad Vitoc,Sergei Gryaznov, Oleg Tudos, Victor ZaporojanJOURNAL OF CLINICAL ONCOLOGY（2024）引用 0|浏览2暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
